期刊文献+

吡格列酮对糖尿病大鼠血液生化指标的影响

下载PDF
导出
摘要 目的:探讨吡格列酮(Piog)对糖尿病大鼠血脂、高敏C反应蛋白(hs-CRP)及生存率的影响。方法:一次性腹腔注射链脲佐菌素制备1型糖尿病模型,大鼠分成3组,Ⅰ组为对照组,Ⅱ组为1型糖尿病组,Ⅲ组为1型糖尿病治疗组。Ⅰ组、Ⅱ组大鼠给予生理盐水灌胃,Ⅲ组大鼠给予吡格列酮灌胃。喂养14周,观察生存率,麻醉后处死取血测定血液生化指标。结果:Piog对胰岛素绝对缺乏的1型糖尿病大鼠血糖无明显影响;与糖尿病未治疗组相比,Piog干预可显著降低低密度脂蛋白、hs-CRP;升高高密度脂蛋白,改善糖尿病大鼠生存率。结论:Piog可改善糖尿病大鼠血脂代谢、炎症标志物表达,可能是其产生有利的心血管系统效应的原因之一。
出处 《实用医学杂志》 CAS 北大核心 2009年第17期2843-2844,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献8

  • 1Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [J]. N EugL J Med, 2007, 356(24): 2457-2471.
  • 2Dormandy J A, Charbonnel B, Eckland D J, PROactive investigators. Secondary prevention of maerovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial In macroVascular Events) : a randomised controlled trial [J]. Lancet, 2005, 366(9493):1279-1289.
  • 3Lincoff A M, Wolski K, Nieholls S J, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials [J]. JAMA, 2007,298 (10) : 1216-1218.
  • 4沈亚非,徐焱成.链脲佐菌素诱导实验性糖尿病大鼠模型建立的研究[J].实用诊断与治疗杂志,2005,19(2):79-80. 被引量:91
  • 5蒋升,谢自敬,张莉.链脲佐菌素诱导1型糖尿病大鼠模型稳定性观察[J].中国比较医学杂志,2006,16(1):16-18. 被引量:45
  • 6Negro R, Dazzi D, Hassan H. Pioglitazone reduces blood pressure in non-dippingdiabetic patients [J]. Minerva Endocrinol, 2004, 29(1): 11-17.
  • 7Kintscher U, Goetze S, Wakino S, et al. Peroxisome proliferator activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes [J]. Eur J Pharmacol, 2000, 401 (3) : 259-270.
  • 8Masayuki A, Hiroyuki T, Toshio N, et al. Peroxisome proliferatoractivated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo [J]. Circulation, 2002,105 (10): 1240-1246.

二级参考文献15

  • 1于德民,吴锐,尹潍,袁咏.实验性链脲佐菌素糖尿病动物模型的研究[J].中国糖尿病杂志,1995,3(2):105-109. 被引量:425
  • 2Ueda H, Ikegami H, Yamato E, et al. The NSY Mouse: a new animal model of spontaneous NIDDM with moderate obesity[J].Diabetologia , 1995,38 : 503
  • 3Rackietan N, Rackietan M L, Nadkarni M R. Studies on diabetogenic action of streptozocin (NSC-37917) [J ]. Cancer Chemother Rep, 1993,29:91
  • 4Pettepher C C, Ledoux S P, Bohr V A, et al. Repair of Alkalilabile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin[J]. J Bio Chem,1991,266:3113
  • 5Lupi R, Dotta F, Marscella L, et al. Prolonged exposure to free fatty acids has cytosatatic and pro-apototic effects on human pancreastic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway and Bcl-2redulated[J]. Diabetes, 2002,51 : 1437
  • 6Mauricio D, Mandrup-Palsen T. Apoptosis and the pathogenesis of IDDM: a question of life and death[J]. Diabetes, 1998,47:1537
  • 7Liuk, Parterson A J, Chin E, et al. Glucose stimulates protein modification by o-linked GlcNAC pancreastic beta cell: Linkage of o-linked GlcNAC to bete cell death [J]. PNAS, 2000,97(6):2820
  • 8Amos A F, Mc Carty D J, Zim Met P [J]. The rising global burden of diabetes and its complications :estimates and projections to the year 2010[J]. Diabet Med, 1997,14(Suppl 5) :SI
  • 9Lynch JJ,Jarvis MF,Kowaluk EA,et al.An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain[J].Eur J Pharmacol,1999,364(2-3):141-146.
  • 10Rackietan N,Rackietan ML,Nadkami MR.Studies on diabetogenic action of streptozotoain[J].Cancer Chermother Reports,1993,29:91-95.

共引文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部